Related Experiment Video
Updated: Jun 17, 2026

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
Ephedrine controls heart rhythms by activating cardiac I(ks) currents
Hongjuan Jing1, Lan Luo, Hui Li
1Huazhong University of Science and Technology, Wuhan, Hubei, China.
Ephedrine (Eph) activates cardiac potassium channels (IKs), increasing heart rate and shortening the QTc interval in mice. This molecular mechanism, involving binding sites on KCNQ1/KCNE1, offers potential for future drug design.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
- Molecular Biology
Background:
- Ephedrine (Eph), derived from Ephedra Sinica, has known effects on the central nervous and cardiovascular systems.
- The precise molecular mechanisms underlying Ephedrine's physiological effects remain largely unelucidated.
Purpose of the Study:
- To investigate the in vivo effects of Ephedrine on heart rate and QTc interval.
- To determine the in vitro influence of Ephedrine on cardiac slowly activated potassium channels (IKs), composed of KCNQ1 and KCNE1 subunits.
Main Methods:
- In vivo studies using BALB/c mice to assess heart rate and QTc interval changes.
- In vitro electrophysiological recordings to analyze Ephedrine's effect on cardiac IKs currents.
- Identification of Ephedrine binding sites on the KCNQ1 channel.
Main Results:
- Ephedrine significantly increased heart rate and shortened the QTc interval in mice, unlike pseudoephedrine.
- Ephedrine markedly activated cardiac IKs currents with an EC50 of 50 nM and shifted G-V curves leftward.
- Binding sites for Ephedrine were identified at F296 and Y299 in the KCNQ1 channel.
Conclusions:
- Ephedrine activates cardiac IKs currents through specific binding interactions with the KCNQ1/KCNE1 channel.
- The identified mechanism provides insights into Ephedrine's cardiovascular effects and suggests potential for KCNQ channel-targeted drug development.
Related Concept Videos
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Cardiopulmonary Resuscitation IV: Pharmacological Management
Heart Failure Drugs: Inotropic Agents
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
